Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
AusperBio completes $120 million Series C financing led by a strategic investor to advance AHB-137 toward commercialization and expand next-generation HBV therapies.
Amount Raised
$120 Million
Round Type
Series C
Investors
Description
AusperBio has closed its $120 million Series C financing. The round saw participation from new investor RA Capital Management and continued support from existing investors. The financing will support the development of AHB-137 and accelerate the company's pipeline expansion. This financing marks a significant milestone for AusperBio as it works on essential therapies for chronic hepatitis B.
Fundz sees it the moment AusperBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
AusperBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.